The Cancer Antigen 125 (CA-125) test is a blood test primarily used to monitor ovarian cancer. CA-125 is a protein that is often found in higher levels in women with ovarian cancer, although it can also be elevated in other conditions, both benign and malignant. The test measures the amount of CA-125 in the blood and is commonly used to gauge treatment effectiveness, track the disease's progression, or check for recurrence after treatment. It’s important to note that while the CA-125 test can provide valuable information, it is not specific to ovarian cancer and should not be used alone for diagnosing the disease.
In clinical settings, the CA-125 test is generally performed alongside other diagnostic tools, such as imaging studies and pelvic examinations. Despite its limitations, including false positives and false negatives, it remains a vital component of managing ovarian cancer. Gynecologists and oncologists may rely on this test to inform their treatment strategies and make clinical decisions about a patient's care. For women at high risk of developing ovarian cancer, such as those with a family history or certain genetic mutations, regular CA-125 testing may be part of a broader surveillance strategy.
Understanding the implications of CA-125 levels requires a nuanced approach. Elevated levels could suggest cancer but may also be associated with other conditions such as endometriosis, fibroids, or pelvic inflammatory disease. Therefore, a comprehensive assessment by a healthcare professional is crucial for interpreting test results accurately. Patients with high CA-125 levels should have a thorough discussion with their healthcare provider to explore the underlying reasons and determine the appropriate next steps in their diagnostic journey.